If you want to go further in your clinical research career, the Institute of Clinical Research (ICR) can help. We provide training, analysis and discussion of the issues facing clinical research today, and opportunities for widening your professional network. Join ICR today, and benefit from all these resources straight away, many of them at specially discounted rates.
Strontium ranelate (Protelos ®) reduced structural progression of osteoarthritis (OA) in knee joints by one third, finds an international phase III study. The trial, presented at the European Congress of Osteoporosis and Osteoarthritis (IOF-ECCEO) meeting in Bordeaux, France, 21 to 24 March, 2012, is the first study ever to have demonstrated a disease modifying effect in OA, with additional benefits shown for pain, function and mobility.
Research proves that green spaces are restorative and therapeutic; they provide a relief from stress, a place for peace, a place for exercise, and a place to create connections with other people in our community.
Kelly Caulfield, Marketing & Communications
Financial and budgetary, IT and green skills top the list of ten skills that Hays’ global offices and clients commonly identify as being in greatest demand.
“Talent shortages are a global problem,” said Simon Lance, Regional Director of Hays in China. “We operate in 31 countries and these skills are the ones that our clients globally say are in most demand. For anyone considering their career options in our globalised economy, these are the skills to focus on.
Kathy Lou, Marketing Manager of Hays in China
This year is another bumper year for employment law changes. In this article we consider the key changes for employers in 2012, planned changes to Employment Tribunal practice and procedure and what changes are still in the pipeline.
Suddenly, perfect storms are developing on the global branding fronts; the top of the agenda is now ‘naming’ of the brands itself and how will the names survive the rapid changes of massive digitalization of social media where such name identities reside and skate to catch customers via global cyber branding.
The boardroom agendas must raise some of these questions. What are the specific tactical options available for the organization at this stage? What are the hot buttons on name evaluation for national or global cyber name branding? What are the key steps to get current name identity ahead of competitors on fast track basis? What are the new digital platforms for mass-customer-acquisition? What are the methodical steps to market domination via name identity?
Many employers will agree with David Cameron, that a decade of Health and Safety rules and regulations intended to protect people, have in fact simply overwhelmed businesses with extra red tape.
Recruiters are very busy people, and typically have little time to read and select CVs for any given role. For them it’s a filtering process, often starting with a pile of CV’s and throwing out the bad ones before reading in more detail, the ones that are left. Therefore your task is NOT to get thrown out with the bathwater, and ensure that your CV is one of the ones that makes it past the first cull!
As we move into 2012, we are witnessing a fundamental change in healthcare product technology market demands from policymakers and consumers alike and a shift in the regulatory needs of manufacturers in this area.
Shayesteh Fürst-Ladani, Managing Director
Building a team of suitably qualified clinical research professionals within the Asia Pacific region, particularly in China, South Korea, Taiwan and India, has become a critical requirement due to the enormous growth in clinical trial activity in the region.
Paula Mumby, Vice President, Operations, Asia Pacific
It is estimated that long term sickness absence costs the UK economy almost £9 billion each year due to 140 million days lost as sickness absence. With an already failing economy, it is no wonder then that alongside a number of employment law reforms aimed at tackling the economic crisis, this is another area under scrutiny.
Employee Value Propositions (EVP) and attractive incentives are once again in focus as employers consider candidates who have potential rather than solely those who are an exact fit for the role, says recruiting experts Hays.
New data on UCB’s anti-TNF biologic certolizumab pegol (Cimzia), disclosed this week in several poster presentations during the annual meeting of the American College of Rheumatology (ACR), show the treatment works well in rheumatoid arthritis (RA) patients irrespective of prior exposure to other biologics, and that results are sustained over 28 weeks.
Olwen Glynn Owen - Pharmiweb Field Reporter
We’re seeing increasing demand for pharma marketing solutions to be based on the iPad, and it’s not hard to see why. The pace at which the industry continues its move away from paper-based detail aids seems to be increasing. But what’s interesting is that remote ‘self-service’ edetailing does not seem to be growing at the same rate. The predicted disintermediation of the traditional field sales model hasn’t happened.
In the aftermath of last year’s inconclusive General Election — and the subsequent emergence of the Coalition Government — you’d have been forgiven for thinking that ‘deficit reduction’ was the only buzzword in town.
Merck Serono, a division of Merck KGaA, Darmstadt Germany, in partnership with the European Head and Neck Society (EHNS), will convene an expert panel of physicians, who will issue a call-to-action that will focus on providing tailored information, advice and better support networks to head and neck cancer patients.
NICE is a world-renowned, independent organisation responsible for providing national recommendations on the use of new and existing medicines and treatments within the NHS, through the Technology Appraisal Programme. The Scientific Advice Programme provides not-for-profit chargeable consulting services to companies who have products in development that may be referred for future evaluation by NICE.
New drug formulations, biological agents, combination therapies and the latest pharmaceutical developments designed to improve outcomes in patients with a wide range of cancers were highlighted at EMCC 2001. Here are just a few of the highlights:
Science is always at its most exciting when it looks to the far horizons. And the unavoidably controversial yet incredibly promising area of stem cell science provides arguably one of the most apt examples.
Esther Dyson the Great Dame of Silicon Valley, at times matriarch to Bill Gates and many other lads on the innovative circuit, wrote a harsh column August 26th on GPS CNN on ICANN gTLD. I like and respect Esther especially her technical background, we have shared the podium, but as this topic deals with the centrality of global corporate nomenclature it demands an authoritative analysis and I feel it’s my responsibility to clarify and taken the liberty to address her entire piece item by item.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her